搜尋
Aytu Biopharma Inc
AYTU添加自選
2.160USD
+0.010+0.47%
收盤 07/01, 16:00（美東）報價延遲15分鐘
23.18M總市值
虧損本益比TTM
關鍵數據
2.130今開
2.190最高
7.28K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.07%換手率
2.150昨收
2.120最低
12.77K成交額
虧損本益比靜
1.63市淨率
0.00%股息率 TTM
-28.93%ROA
3.06552週最高
0.32量比
-13.56M淨利潤
10.73M總股本
-4.6080每股盈餘TTM
0.25Beta
-97.42%ROE
1.46052週最低
3.26%振幅
55.10%毛利率
23.18M總市值
0.71回報/風險
3.37%風險率
TradingKey Aytu Biopharma Inc股票評分
單位: USD 更新時間: 2026-06-30操作建議
Aytu Biopharma Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在藥品行業排名85/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為9.50。中期看，股價處於下降通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Aytu Biopharma Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Aytu Biopharma Inc亮點
亮點風險
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
業績增長期
公司處於發展階段，最新年度總收入66.38M美元
估值高估
公司最新PE估值-0.47，處於3年歷史高位
機構減倉
最新機構持股3.87M股，環比減少11.30%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉0.00股
分析師目標
基於
3
分析師
買入
評級
9.500
目標均價
+341.86%
漲幅空間
Aytu Biopharma Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Aytu Biopharma Inc簡介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
公司代碼AYTU
公司Aytu Biopharma Inc
CEODisbrow (Joshua R)
網址https://aytubio.com/
相關品種
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%熱門品種
52263.700
+9.400 (+0.02%)
29841.200
+41.900 (+0.14%)
7481.900
+6.400 (+0.09%)
15354.000
-1.000 (-0.01%)
69651.000
+166.000 (+0.24%)
6279.300
+3.900 (+0.06%)
67.914
-0.054 (-0.08%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4039.330
+8.560 (+0.21%)
常見問題
Aytu Biopharma Inc(AYTU)的當前股價是多少？
Aytu Biopharma Inc(AYTU)的當前股價是 2.15。
Aytu Biopharma Inc 的股票代碼是什麼？
Aytu Biopharma Inc的股票代碼是AYTU。
Aytu Biopharma Inc股票的52週最高點是多少？
Aytu Biopharma Inc股票的52週最高點是3.06。
Aytu Biopharma Inc股票的52週最低點是多少？
Aytu Biopharma Inc股票的52週最低點是1.46。
Aytu Biopharma Inc的市值是多少？
Aytu Biopharma Inc的市值是23.08M。
現在Aytu Biopharma Inc(AYTU)的股票是買入、持有還是賣出？
根據分析師評級，Aytu Biopharma Inc(AYTU)的總體評級為買入，目標價格為9.50。
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是多少
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是-2.16。